Cargando…
Preserving mitochondria to treat hypertrophic cardiomyopathy: From rare mitochondrial DNA mutation to heart failure therapy?
Hypertrophic cardiomyopathy and pathological cardiac hypertrophy are characterized by mitochondrial structural and functional abnormalities. In this issue of the JCI, Zhuang et al. discovered 1-deoxynojirimycin (DNJ) through a screen of mitochondrially targeted compounds. The authors described the e...
Autor principal: | Diwan, Abhinav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348762/ https://www.ncbi.nlm.nih.gov/pubmed/37463442 http://dx.doi.org/10.1172/JCI171965 |
Ejemplares similares
-
Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy
por: Liu, Jie, et al.
Publicado: (2022) -
Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?
por: Vosberg, Hans-Peter
Publicado: (2000) -
Mechanistic complexity of contractile dysfunction in hypertrophic cardiomyopathy
por: Regnier, Michael
Publicado: (2018) -
Effect of sarcomere and mitochondria-related mutations on myocardial fibrosis in patients with hypertrophic cardiomyopathy
por: Chung, Hyemoon, et al.
Publicado: (2021) -
Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy
por: Melacini, Paola, et al.
Publicado: (2010)